No Data
Abbott Labs Lifts FY24 Outlook After 2Q Sales Rise
By Dean Seal Abbott Laboratories raised its full-year earnings guidance after reporting sales gains in the second quarter from its nutrition and medical devices segments. The Abbott Park, Ill.-based
BTIG Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135
BTIG analyst Marie Thibault maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $135.According to TipRanks data, the analyst has a success rate of 31.7% and
Maintained Buy Rating for Abbott Laboratories on Strong Financials and Growth Prospects
Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the "Neutral" zone on Thursday.U.S. stocks closed lower on Thursday, with the Dow Jones
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
TD Cowen analyst Josh Jennings maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 53.1%
Buy Rating Affirmed on Abbott Laboratories Amid Strong Q2 Results and Raised 2024 Guidance